article thumbnail

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Pharmacy Times

Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted. billion worth in savings in 2023 and $36 billion since the first biosimilar entered the market in 2015.

article thumbnail

Zai Lab at ASCO 2025: Rafael G. Amado in an Illuminating Dialogue Exchange with PharmaShots 

PharmaShots

ADCs continue to possess the potential to provide a more impactful benefit to patients than chemotherapy alone, with a more limited toxicity profile. All patients in the study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. and 30% from China. mg/kg, 1.2

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evaluating Changes in Systemic Anticancer Therapy Use Between 2015 and 2019

Drug Topics

While the use of chemotherapy at end of life is decreasing, the use of immunotherapy is increasing.

article thumbnail

2nd Hit ID Summit

pharmaphorum

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market.

article thumbnail

NICE recommends first CAR-T cell therapy on NHS in England

pharmaphorum

Yescarta is administered to the patient via a single intravenous infusion following the administration of a round of chemotherapy designed to accommodate the new cells and minimise the patient’s immune reaction to them. About 50% will ultimately relapse post-transplant.

article thumbnail

Rebranded Servier eyes €3bn in cancer drug sales by 2030

pharmaphorum

The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.